Suraksha Diagnostic Limited is one of India’s leading diagnostic chains that is looking to raise ₹846.25 crore through its Initial Public Offering (IPO). This IPO provides a good opportunity for investors who are keen to invest in the growing healthcare and diagnostic sector. Here, you will find all the essential details about the Suraksha Diagnostic IPO, including company insights, financials, the IPO timeline, and the benefits of investing.
About Suraksha Diagnostic Limited
Suraksha Diagnostic Limited, incorporated in 2005, offers full pathology, radiology, and medical consultancy services.
Key Services Offered:
- Pathology and radiology testing.
- Fast digital reporting via advanced platforms.
- Vaccination services and customized testing packages.
- Use of AI and digital pathology for accuracy and efficiency.
Competitive Strengths:
- Strong presence in Eastern and Northeastern India.
- 44 diagnostic centers, 166 sample collection points, and over 750 doctors in its network.
- Advanced systems like LIMS, RIS, and PACS for smooth operations.
Suraksha Diagnostic IPO Details
- IPO Opening Date: November 29, 2024
- IPO Closing Date:December 3, 2024
- Listing Date:December 6, 2024
- Issue Size:₹846.25 Crore (OFS: 1.92 Crore Shares)
- Price Band:₹420 to ₹441 per share
- Lot Size:34 shares (₹14,994)
- Listing Platforms:BSE, NSE
- Face Value:₹2 per share
- Issue Type:Book Built Issue
IPO Receiving Details:
- QIB (20%): 38,37,867 shares
- NII (15%): 28,78,400 shares
- sNII (< ₹10L): 9,59,466 shares
- bNII (> ₹10L): 19,18,934 shares
- Retail Investors (35%): 67,16,266 shares
- Anchor Investors (30%): 57,56,797 shares
Suraksha Diagnostic IPO Dates
- Anchor Investor Bidding: November 28, 2024
- IPO Opening Date: November 29, 2024
- IPO Closing Date: December 3, 2024
- Share Allotment Date: December 4, 2024
- Refunds Initiated: December 5, 2024
- Shares Credited to Demat: December 5, 2024
- Listing Date: December 6, 2024
Important Ratios (FY 2024):
- Return on Equity (ROE): 14.09%
- Return on Capital Employed (ROCE): 21.46%
- Debt-to-Equity Ratio: 0.2
- PAT Margin: 10.57%
Objects of the IPO
The IPO is fully an Offer for Sale (OFS), and the proceeds will flow to the selling shareholders and not directly to the company from the issue.
Why invest in Suraksha Diagnostic IPO?
- Rising health care and diagnostic service demands in India.
- Good geographical presence in the Eastern and Northeastern regions.
- Digital and AI-based operations guarantee high accuracy and efficiency.
- Consistent improvement in financial performance.
- Experienced management team with industry expertise.
Expert Review
Experts feel that Suraksha Diagnostic IPO can be a good prospect for long-term investment given the company’s growth plans, its robust operations, and trajectory of finances. However, since the issue is completely priced, short-term risk may exist for speculative investors.
Conclusion
The Suraksha Diagnostic IPO is an opportunity for investment in the healthcare and diagnostic space. Strong regional presence, technology-driven processes, and consistent financial growth make the company a good one for further expansion.
For all the latest updates and insights into investment opportunities, financial news, and much more, stay connected with TechTalksWorld. Make informed decisions and grow your wealth effectively!
